These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 28696345)

  • 1. Optimal HIV Postexposure Prophylaxis Regimen Completion With Single Tablet Daily Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine Compared With More Frequent Dosing Regimens.
    Mayer KH; Jones D; Oldenburg C; Jain S; Gelman M; Zaslow S; Grasso C; Mimiaga MJ
    J Acquir Immune Defic Syndr; 2017 Aug; 75(5):535-539. PubMed ID: 28696345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of tolerability with the co-formulation elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate for post-HIV exposure prophylaxis.
    Valin N; Fonquernie L; Daguenel A; Campa P; Anthony T; Guiguet M; Girard PM; Meyohas MC
    BMC Infect Dis; 2016 Nov; 16(1):718. PubMed ID: 27894270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-tablet regimen of emtricitabine/tenofovir disoproxil fumarate plus cobicistat-boosted elvitegravir increase adherence for HIV postexposure prophylaxis in sexual assault victims.
    Malinverni S; Bédoret F; Bartiaux M; Gilles C; De Wit S; Libois A
    Sex Transm Infect; 2021 Aug; 97(5):329-333. PubMed ID: 33106437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data.
    Mills A; Crofoot G; Ortiz R; Rashbaum B; Towner W; Ward D; Brinson C; Kulkarni R; Garner W; Ebrahimi R; Cao H; Cheng A; Szwarcberg J
    HIV Clin Trials; 2014; 15(2):51-6. PubMed ID: 24710918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis.
    Inciarte A; Leal L; González E; León A; Lucero C; Mallolas J; Torres B; Laguno M; Rojas J; Martínez-Rebollar M; González-Cordón A; Cruceta A; Arnaiz JA; Gatell JM; García F;
    J Antimicrob Chemother; 2017 Oct; 72(10):2857-2861. PubMed ID: 29091217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-administration of elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine and atazanavir in treatment-experienced HIV patients.
    Biagi M; Badowski ME; Chiampas T; Young J; Patel M; Vaughn P
    Int J STD AIDS; 2017 Jul; 28(8):766-772. PubMed ID: 27587601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF.
    Gathe J; Arribas JR; Van Lunzen J; Garner W; Speck RM; Bender R; Shreay S; Nguyen T
    Patient; 2015 Oct; 8(5):445-54. PubMed ID: 26286337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-Tablet Emtricitabine-Rilpivirine-Tenofovir as HIV Postexposure Prophylaxis in Men Who Have Sex With Men.
    Foster R; McAllister J; Read TR; Pierce AB; Richardson R; McNulty A; Carr A
    Clin Infect Dis; 2015 Oct; 61(8):1336-41. PubMed ID: 26123937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virological failure in two patients with HIV-1 RNA viral loads >1,000,000 copies/ml initiated on elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.
    Adams JL; Byrne D; Pepe R; Gray A; Baxter JD
    Antivir Ther; 2016; 21(2):175-80. PubMed ID: 26308882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Tolerability of Once Daily Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Exposure.
    Mayer KH; Gelman M; Holmes J; Kraft J; Melbourne K; Mimiaga MJ
    J Acquir Immune Defic Syndr; 2022 May; 90(1):27-32. PubMed ID: 34991141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV.
    Devred I; Kayembe K; Valin N; Rougier H; Shinga BW; Lambert-Niclot S; Chiarabini T; Meyohas MC; Lacombe K
    BMC Infect Dis; 2023 Sep; 23(1):578. PubMed ID: 37667182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Raltegravir, tenofovir DF, and emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence.
    Mayer KH; Mimiaga MJ; Gelman M; Grasso C
    J Acquir Immune Defic Syndr; 2012 Apr; 59(4):354-9. PubMed ID: 22267017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dolutegravir with tenofovir disoproxil fumarate-emtricitabine as HIV postexposure prophylaxis in gay and bisexual men.
    McAllister JW; Towns JM; Mcnulty A; Pierce AB; Foster R; Richardson R; Carr A
    AIDS; 2017 Jun; 31(9):1291-1295. PubMed ID: 28301425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and adherence of bictegravir/emtricitabine/tenofovir alafenamide for HIV post-exposure prophylaxis among adults in Guiyang China: a prospective cohort study.
    Gan L; Xie X; Fu Y; Yang X; Ma S; Kong L; Song C; Song Y; Ren T; Long H
    BMC Infect Dis; 2024 Jun; 24(1):565. PubMed ID: 38844855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination Therapy with Tenofovir Disoproxil Fumarate/Emtricitabine/Elvitegravir/Cobicistat Plus Darunavir Once Daily in Antiretroviral-Naive and Treatment-Experienced Patients: A Retrospective Review.
    Naccarato MJ; Yoong DM; Fong IW; Gough KA; Ostrowski MA; Tan DHS
    J Int Assoc Provid AIDS Care; 2018; 17():2325957417752260. PubMed ID: 29385867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects.
    Ramanathan S; Custodio JM; Wei X; Wang H; Fordyce M; Dave A; Ling KH; Szwarcberg J; Kearney BP
    J Acquir Immune Defic Syndr; 2016 Jul; 72(3):281-8. PubMed ID: 26885802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine.
    Cid-Silva P; Fernández-Bargiela N; Margusino-Framiñán L; Balboa-Barreiro V; Mena-De-Cea Á; López-Calvo S; Vázquez-Rodríguez P; Martín-Herranz I; Míguez-Rey E; Poveda E; Castro-Iglesias Á
    Basic Clin Pharmacol Toxicol; 2019 Apr; 124(4):479-490. PubMed ID: 30388308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Choice of antiretroviral drugs for postexposure prophylaxis for adults and adolescents: a systematic review.
    Ford N; Shubber Z; Calmy A; Irvine C; Rapparini C; Ajose O; Beanland RL; Vitoria M; Doherty M; Mayer KH
    Clin Infect Dis; 2015 Jun; 60 Suppl 3():S170-6. PubMed ID: 25972499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and bioequivalence evaluation of single-tablet and separate-tablet regimens for once-daily cobicistat-boosted elvitegravir in healthy Japanese male subjects: A randomized, two-way crossover study.
    Shiomi M; Matsuki S; Ikeda A; Ishikawa T; Nishino N; Kimura M; Kumagai Y; Irie S
    Clin Pharmacol Drug Dev; 2015; 4(3):218-25. PubMed ID: 27140802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Trial of a Single-tablet Regimen of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate for the Initial Treatment of Human Immunodeficiency Virus Type 2 Infection in a Resource-limited Setting: 48-Week Results From Senegal, West Africa.
    Ba S; Raugi DN; Smith RA; Sall F; Faye K; Hawes SE; Sow PS; Seydi M; Gottlieb GS;
    Clin Infect Dis; 2018 Oct; 67(10):1588-1594. PubMed ID: 29672676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.